Skip to content
‹ Back to IndustriesSciences

Richard Branson Reflects on Being in Space, What it Means for Virgin Galactic’s Future

Virgin Galactic completed a successful test flight to space last weekend, signaling a massive jump in the space tourism market. On board was none other than Virgin Founder Sir Richard Branson himself. Tune in below to see his thoughts on being a passenger on the vessel and what it means for the future of the…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · BloombergOuter SpaceRichard BransonSpace Tourism
Share

Key takeaways

01

Virgin Galactic completed a successful test flight to space last weekend, signaling a massive jump in the space tourism market.

02

On board was none other than Virgin Founder Sir Richard Branson himself.

03

Tune in below to see his thoughts on being a passenger on the vessel and what it means for the future of the…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Virgin Galactic completed a successful test flight to space last weekend, signaling a massive jump in the space tourism market. On board was none other than Virgin Founder Sir Richard Branson himself. Tune in below to see his thoughts on being a passenger on the vessel and what it means for the future of the company and space travel as a whole.

Branson: I’d been practicing some words to say to kids down on Earth for some time, and once I’m on it, once I’d done those words, just being able to unbuckle and then just take off and look out these massive windows, then the spaceship was upside down and taken the Earth from space. It was that something I’ve dreamt of since I was a kid. And it was completely and utterly awesome. And I Yeah. You know, one of those dreams come true. And I still think that I’m going to wake up any minute. And it’s all a dream.

Host: You did touch back down. You said that the feeling of weightlessness is indescribable, but will you at least have an attempt for me?

Branson: Well, it’s just the most. And it is. It’s just I mean, it wasn’t just the sort of floating, but then looking at the other three beneath me, because you just floating as well. And then looking out through these gigantic windows back at this stunningly beautiful Earth below, you know, I mean, like pristine, pristine sky, the strength of the blues and the Blacks. And and I think we were in space. And I’ve know, I’ve never know, I’ve always sort of pictured what it was going to be like. I mean, you know, like the ride up there, the ride back. And I never realized that the whole experience is going to be so vivid.

Host: What does today symbolize for the company, and also for those children that were present earlier?

Branson: For the children we’ve just got to get building as many spaceships as we can as fast as we can. So that one that one day those kids will have the chance to have a similar experience or what I had and that we will do. We also launched this giant global raffle today. So that, you know, two kids, you know, just $10 for a pair of tickets. If they could win the raffle, they can go out. But that money will hopefully enable many, many people to be able to go up who could never have dreamt of going to space.

*Bloomberg contributed to this content

—

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Video TranscriptExpand ↓

I've been practicing some words to say to kids down on Earth for some time, and once I'm on it, once I'd done those words, just being able to unbuckle and then just take off and look out these massive windows, then the spaceship was upside down and taken the Earth from space. It was that something I've dreamt of since I was a kid. And it was completely and utterly awesome. And I Yeah. You know, one of those dreams come true. And I still think that I'm going to wake up any minute. And it's all a dream. It was just to your hair. You did touch back down. You said that the feeling of weightlessness is indescribable, but will you at least have an attempt for me? Well, it's just the most. And it is. It's just I mean, it wasn't just the sort of floating, but then looking at the other three beneath me, because you just floating as well. And then looking out through these gigantic windows back at this stunningly beautiful Earth below, you know, I mean, like pristine, pristine sky, the strength of the blues and the Blacks. And and I think we were in space. And I've know, I've never know, I've always sort of pictured what it was going to be like. I mean, you know, like the ride up there, the ride back. And I never realized that the whole experience is going to be so vivid and well beyond sort of the satisfaction of your own goal was being achieved. What does today symbolize for the company, and also for those children that were present earlier? And we've looked for the children. We've just got to get building as many spaceships as we can as fast as we can. So that one that one day those kids will have the chance to have a similar experience or what I had and that we will do. We also launched this giant global raffle today. So that, you know, two kids, you know, just $10 for a pair of tickets. If they could win the raffle, they can go out. But that money will hopefully enable many, many people to be able to go up who could never have dreamt of going to space.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512